Composition Comprising (R)-Spiro[L-Azabicyclo[2.2.2]Octane-3,2'(3'H)-Furo[2,3-B]Pyridine (AZD0328) and its Use in the Treatment of Alzheimer's Disease, ADHD or Cognitive Dysfunction

A method of providing relief of memory loss or cognitive deficiency in a subject with Alzheimer's Disease, Attention-Deficit/Hyperactivity Disorder (ADHD), Cognitive dysfunction in association with Schizophrenia or Cognitive dysfunction, comprising:

• administering to a patient in need thereof, at least one therapeutically effective dose in the range of about 0.0005 milligram to about 2.0 milligram of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine].

A method to ameliorate cognitive deficits in patients with schizophrenia comprising:

• administering to a patient in need thereof, at least one therapeutically effective dose in the range of about 0.0005 milligram to about 2.0 milligram of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine].

A method of ameliorating cognitive deficits in subjects with schizophrenia comprising:

• identifying a subject with schizophrenia;
• administering to said subject at least one therapeutically effective dose of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine];
• wherein said dose is in the range of about 0.0005 milligram to about 2.0 milligram.

A pharmaceutical composition comprising an amount of (R)-spiro[1-azabicyclo[2.2.2]octane-3,2′(3′H)-furo[2,3-b]pyridine] between about 0.0005 milligram and about 2.0 milligram per unit dose together with at least one pharmaceutically-acceptable excipient, diluent, or carrier.

14-25. (canceled)